Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| Formally-35MRB2 | |||
| MK0869-065 | |||
| 2006_405 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression.
The duration of treatment is 20 months.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| aprepitant | Drug |
| ||
| Comparator: placebo (unspecified) | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| Total HAMD-17 score </= 10 after 10 weeks of treatment, time to relapse of depression over 6-10 months | after 10 weeks of treatment and over 6-10 months |
| Measure | Description | Time Frame |
|---|---|---|
| CGI-S score change from Week 10 at Month 6; HAMD-17 total score change from Week 10 at Month 6; an HAMA total score change from week 10 at Month 6. | Week 10 at Month 6 |
Not provided
Patients with Major Depressive Disorder
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Monitor | Merck Sharp & Dohme LLC | Study Director |
Not provided
Not provided
Not provided
| ID | Type | URL | Comment |
|---|---|---|---|
| CSR Synopsis Link | View IPD |
| ID | Term |
|---|---|
| D003865 | Depressive Disorder, Major |
| ID | Term |
|---|---|
| D003866 | Depressive Disorder |
| D019964 | Mood Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077608 | Aprepitant |
| ID | Term |
|---|---|
| D009025 | Morpholines |
| D010078 | Oxazines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided